A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy.

Cancer
Caitlyn T SolemJorge E Cortes

Abstract

In a randomized study, glasdegib (a hedgehog inhibitor) plus low-dose cytarabine (LDAC) significantly prolonged survival in comparison with LDAC in patients with acute myeloid leukemia (AML). A quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) approach was used to evaluate comparative quality-adjusted survival. Overall survival was partitioned into the following: time with any treatment-emergent grade 3 or higher adverse events (TOX); time without symptoms of disease progression or toxicity (TWiST); and time after treatment discontinuation due to insufficient clinical response, relapse, or death time after progression (REL). Q-TWiST was calculated by multiplying the restricted mean time in each state by respective utilities and then summing up the utility-adjusted time. At 20 months of follow-up, the survival probabilities for the glasdegib-LDAC arm and the LDAC arm were 28.2% and 7.9%, respectively. Glasdegib-LDAC patients (n = 78), in comparison with LDAC patients (n = 38), had significantly longer mean TWiST (+3.4 months; 95% confidence interval [CI], 1.8-5.2 months) and TOX (+0.8 months; 95% CI, 0.1-1.6 months) and longer but nonsignificant REL (+0.3 months; 95% CI, -1.9 to 2.3 months). Q-T...Continue Reading

References

Jan 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A GoldhirschA S Coates
Dec 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R D Gelber, A Goldhirsch
Jul 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B F ColeA Goldhirsch
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B ZeeJ Pater
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S K ParsonsR D Gelber
Jul 5, 2001·Journal of Clinical Epidemiology·V LevyUNKNOWN French Cooperative CLL Group
May 23, 2002·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·R PorcherPh Ravaud
Mar 21, 2006·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Dennis A RevickiBernard F Cole
Jun 24, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lowell E Schnipper American Society of Clinical Oncology
Mar 16, 2017·Cancer·Olga Husson, Robin L Jones
Feb 7, 2018·Expert Review of Pharmacoeconomics & Outcomes Research·Caitlyn T SolemMarc F Botteman
Feb 22, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael R SavonaJorge E Cortes

❮ Previous
Next ❯

Citations

Feb 7, 2021·Clinical Lymphoma, Myeloma & Leukemia·Jonathan FeldShyamala C Navada

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01546038

Software Mentioned

TWiST

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.